Data from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC

<div>AbstractPurpose:<p>To uncover the underpinnings of acquired resistance (AR) to immunotherapy (IO), we determined whether distinctive clinicopathologic, radiomic, and peripheral blood (PB) immune-inflammatory features reflect oligo- and systemic (sys)-AR in patients with advanced non–small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor therapy.</p>Experimental Design:<p>On 105 consecutive patients with IO-treated advanced NSCLC, PB immunophenotypes, cytokines, and CT-derived radiomic features (RF), extracted from primary and merged metastatic lesions, were prospectively collected at baseline (T0) and at the first disease assessment (T1, 9–12 weeks), and their Δ variation [(T1−T0)/T0] was computed. AR, defined as progression after the initial response (complete/partial) or stable disease ≥6 months, was subdivided according to the number of new and/or progressive lesions in oligoAR (≤3) and sysAR (>3). Clinicopathologic, PB, and radiomic parameters and survival outcomes were statistically correlated to AR patterns.</p>Results:<p>OligoAR and sysAR involved 24% and 12.4% of cases, respectively. Whereas baseline PB immune profiles were comparable, a Δ^pos cytotoxic (NK, CD8⁺granzyme B⁺) and Δ^neg immunosuppressive (CD14⁺ monocytes) dynamic coupled with different modulations of IL-6, TGF-β1, TNFα, and soluble PD-L1 represented distinctive features of oligoAR versus sysAR (<i>P</i> < 0.05). Significantly longer postprogression survival characterized oligoAR versus sysAR (median 20.3 vs. 5.6 months; HR, 0.22; <i>P</i> < 0.001). The number and sites of oligoAR involvement appeared to condition the blood immune background (<i>P</i> < 0.05) and survival. ΔRFs outperformed baseline RFs, with 15 ΔRFs sharply discriminating oligoAR from sysAR (<i>P</i> range: <0.001–0.04). ROC analysis confirmed the optimal performance of top-ranked ΔRFs (AUC range: 0.88–0.99).</p>Conclusions:<p>Longitudinal analysis of blood-immune hallmarks and radiomic descriptors may decipher distinct patterns of AR to IO in advanced patients with NSCLC.</p><p><a href="https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-4297" target="_blank"><i>See related commentary by Jeng and Schoenfeld, p. 1381</i></a></p></div>